Pfizer Aktie News

Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market.

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immediately delivers advanced-stage obesity assets, strengthening PFE's competitive positioning in a high-growth market. Management plans to advance roughly 15 programs in 2026, supported by elevated R&D...

Pfizer has been struggling for several years. The company's pipeline could help it turn things around.

Ares Capital offers an especially juicy dividend. Energy Transfer has an impressive track record of increasing its distribution each quarter.

Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result.

The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold.

Generating meaningful dividend income from modest capital requires disciplined stock selection and a clear mathematical framework. An allocation of $2,670 distributed equally across three carefully vetted ultra-high-yield securities, each offering yields exceeding 6%, can reasonably generate approximately $300 in annual dividend income.

Both companies have faced some headwinds recently, but the core businesses and dividend payouts remain strong. Blackstone is the top alternative asset manager in the world and operates as a premier global investment firm for institutional and individual investors.